Repositorio UFRO · Omeka S

Epothilones as Natural Compounds for Novel Anticancer Drugs Development

Primer Autor	Paz, Cristian
Co-autores	Villegas, Cecilia Gonzalez-Chavarria, Ivan Burgos, Viviana Iturra-Beiza, Hector Ulrich, Henning
Título	Epothilones as Natural Compounds for Novel Anticancer Drugs Development
Editorial	MDPI
Revista	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Lenguaje	en
Resumen	Epothilone is a natural 16-membered macrolide cytotoxic compound produced by the metabolism of the cellulose-degrading myxobacterium Sorangium cellulosum. This review summarizes results in the study of epothilones against cancer with preclinical results and clinical studies from 2010-2022. Epothilone have mechanisms of action similar to paclitaxel by inducing tubulin polymerization and apoptosis with low susceptibility to tumor resistance mechanisms. It is active against refractory tumors, being superior to paclitaxel in many respects. Since the discovery of epothilones, several derivatives have been synthesized, and most of them have failed in Phases II and III in clinical trials, however, ixabepilone and utidelone are currently used in clinical practice. There is robust evidence that triple-negative breast cancer (TNBC) treatment improves using ixabepilone plus capecitabine or utidelone in combination with capecitabine. In recent years innovative synthetic strategies resulted in the synthesis of new epothilone derivatives with improved activity against refractory tumors with better activities when compared to ixabepilone or taxol. These compounds together with specific delivery mechanisms could be developed in anti-cancer drugs.
Fecha Publicación	2023
Tipo de Recurso	artículo de revisión
doi	10.3390/ijms24076063
Formato Recurso	PDF
Palabras Claves	epothilones epothilone derivates cytotoxicity anticancer agents refractory cancer taxanes clinical trials
Ubicación del archivo	http://dx.doi.org/10.3390/ijms24076063
Categoría OCDE	Bioquímica y biología molecular Química
Materias	epotilonas derivados de epotilona citotoxicidad agentes anticancerígenos cáncer refractario taxanos ensayos clínicos
Identificador del recurso (Mandatado-único)	artículo de revisión
Versión del recurso (Recomendado-único)	versión publicada
License	CC BY 4.0
Condición de la licencia (Recomendado-repetible)	CC BY 4.0
Derechos de acceso	acceso abierto
Access Rights	acceso abierto
Id de Web of Science	WOS:000969832300001
ISSN	1661-6596
Tipo de ruta	verde# dorado
Categoría WOS	Bioquímica y biología molecular Química
Referencia del Financiador (Mandatado si es aplicable-repetible)	FAPESP 2018/07366-4 FAPESP 201808426-0 ANID-FONDECYT 1220831 ANID FONDECYT 11181105 ANID FONDECYT 1220831